STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)
|
6 Months Ended |
Dec. 31, 2025 |
|---|
| Class of Warrant or Right [Line Items] |
|
| SCHEDULE OF STOCK OPTIONS ACTIVITY |
Activity
in the Company’s stock options during the six months ended December 31, 2025 and related balances outstanding as of that date are
reflected below:
SCHEDULE OF STOCK OPTIONS ACTIVITY
| |
|
Number of
Shares |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contract
Term
(# years) |
|
|
Aggregate
intrinsic
Value |
|
|
Weighted
Average
Grant Date
Fair Value |
|
| Outstanding at June 30, 2025 |
|
|
796,660 |
|
|
$ |
4.10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted |
|
|
536,239 |
|
|
|
1.88 |
|
|
|
|
|
|
|
|
|
|
$ |
1.23 |
|
| Exercised |
|
|
(62,125 |
) |
|
|
4.10 |
|
|
|
|
|
|
$ |
115,000 |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(193,167 |
) |
|
|
3.89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding at December 31, 2025 |
|
|
1,077,607 |
|
|
|
3.03 |
|
|
|
8.05 |
|
|
|
– |
|
|
|
|
|
| Exercisable at December 31, 2025 |
|
|
424,574 |
|
|
|
4.01 |
|
|
|
6.56 |
|
|
|
– |
|
|
|
|
|
Activity
in the Company’s stock options during the six months ended December 31, 2024 and related balances outstanding as of that date are
reflected below:
| |
|
Number of
Shares |
|
|
Weighted
Average
Exercise
Price |
|
|
Weighted
Average
Remaining
Contract
Term
(# years) |
|
|
Aggregate
intrinsic
Value |
|
|
Weighted
Average
Grant Date
Fair Value |
|
| Outstanding at June 30, 2024 |
|
|
1,605,060 |
|
|
$ |
4.85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
$ |
– |
|
| Exercised |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
$ |
– |
|
|
|
|
|
| Forfeited and cancelled |
|
|
(111,782 |
) |
|
|
3.39 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding at December 31, 2024 |
|
|
1,493,278 |
|
|
|
4.96 |
|
|
|
7.38 |
|
|
|
– |
|
|
|
|
|
| Exercisable at December 31, 2024 |
|
|
757,220 |
|
|
|
6.39 |
|
|
|
6.20 |
|
|
|
– |
|
|
|
|
|
|
| SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS |
The
Company uses the Black-Scholes valuation model to calculate the fair value of stock options at the date of grant. Weighted average annualized
percentages and expected term inputs used in Black-Scholes valuations during the periods listed below are:
SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS
| |
|
Six months ended December 31, |
|
| |
|
2025 |
|
|
2024 (1) |
|
| Expected volatility |
|
|
95.46 |
% |
|
|
- |
|
| Risk free interest rate |
|
|
3.85 |
% |
|
|
- |
|
| Dividend yield |
|
|
– |
% |
|
|
- |
|
| Expected term (years) |
|
|
5.87 |
|
|
|
|
|
| (1) |
|
No stock options were issued during the six months ended December 31 2024. |
|
| SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY |
Activity
in RSUs, including PSUs, during the six months ended December 31, 2025 and related balances outstanding as of that date are reflected
below:
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
| |
|
Number
of
Shares |
|
|
Weighted
Average Grant
Date Fair
Value |
|
|
Weighted Average
Remaining Contract
Term (# years)
|
|
| Outstanding at June 30, 2025 |
|
|
200,000 |
|
|
$ |
1.60 |
|
|
|
|
|
| Granted |
|
|
304,878 |
|
|
|
1.43 |
|
|
|
|
|
| Vested and settled |
|
|
– |
|
|
|
– |
|
|
|
|
|
| Forfeited and cancelled |
|
|
– |
|
|
|
– |
|
|
|
|
|
| Outstanding at December 31, 2025 |
|
|
504,878 |
|
|
|
1.49 |
|
|
|
1.67 |
|
Activity
in RSUs during the six months ended December 31, 2024 and related balances outstanding as of that date are reflected below:
| |
|
Number
of
Shares |
|
|
Weighted
Average Grant
Date Fair
Value |
|
| Outstanding at June 30, 2024 |
|
|
114,666 |
|
|
$ |
5.56 |
|
| Granted |
|
|
– |
|
|
|
– |
|
| Vested and settled |
|
|
– |
|
|
|
– |
|
| Forfeited and cancelled |
|
|
(740 |
) |
|
|
5.75 |
|
| Outstanding at December 31, 2024 |
|
|
113,926 |
|
|
|
5.56 |
|
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES |
The
following table summarizes SBC expense:
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSES
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
Three months ended December 31, |
|
|
Six
months ended December 31, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Selling and administrative |
|
$ |
264,000 |
|
|
$ |
250,000 |
|
|
$ |
474,000 |
|
|
$ |
569,000 |
|
| Research and development |
|
|
21,000 |
|
|
|
28,000 |
|
|
|
20,000 |
|
|
|
56,000 |
|
| Total stock-based compensation expense |
|
$ |
285,000 |
|
|
$ |
278,000 |
|
|
$ |
494,000 |
|
|
$ |
625,000 |
|
|
| Pre-funded Preferred Stock Warrant [Member] |
|
| Class of Warrant or Right [Line Items] |
|
| SCHEDULE OF STOCK WARRANT ACTIVITY |
The
Company’s Prefunded Preferred Stock warrants do not expire. Activity during the six months ended December 31, 2025 is
reflected below:
SCHEDULE OF STOCK WARRANT ACTIVITY
| |
|
Number of
Warrants |
|
|
Weighted Average
Exercise Price Per
Warrant |
|
| Outstanding and exercisable at June 30, 2025 |
|
|
– |
|
|
$ |
– |
|
| Issued |
|
|
258,144 |
|
|
|
0.001 |
|
| Exercised |
|
|
– |
|
|
|
– |
|
| Forfeited and cancelled |
|
|
– |
|
|
|
– |
|
| Outstanding and exercisable at December 31, 2025 |
|
|
258,144 |
|
|
|
0.001 |
|
|
| Warrant [Member] |
|
| Class of Warrant or Right [Line Items] |
|
| SCHEDULE OF STOCK WARRANT ACTIVITY |
Activity
in the Company’s common stock warrants during the six months ended December 31, 2025 is reflected below:
SCHEDULE OF STOCK WARRANT ACTIVITY
| |
|
Number
of
Warrants |
|
|
Weighted
Average
Exercise Price Per
Warrant |
|
|
Weighted Average
Remaining
Contract Term
(# years)
|
|
| Outstanding and exercisable at June 30, 2025 |
|
|
1,413,110 |
|
|
$ |
6.14 |
|
|
|
|
|
| Issued |
|
|
1,214,766 |
|
|
|
1.72 |
|
|
|
|
|
| Exercised |
|
|
– |
|
|
|
– |
|
|
|
|
|
| Expired and cancelled |
|
|
(131,678 |
) |
|
|
4.80 |
|
|
|
|
|
| Outstanding and exercisable at December 31, 2025 |
|
|
2,496,198 |
|
|
|
4.06 |
|
|
|
2.86 |
|
Activity
in the Company’s common stock warrants during the six months ended December 31, 2024 is reflected below:
| |
|
Number of
Warrants
|
|
|
Weighted Average
Exercise Price Per
Warrant |
|
| Outstanding and exercisable at June 30, 2024 |
|
|
1,413,110 |
|
|
$ |
6.14 |
|
| Issued |
|
|
- |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
| Expired and cancelled |
|
|
- |
|
|
|
- |
|
| Outstanding and exercisable at December 31, 2024 |
|
|
1,413,110 |
|
|
|
6.14 |
|
|